Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Figure 1

Proportion of the sample on treatment and type of treatment since disease onset. The vast majority of patients at onset were treated with group 2 treatments (interferons/glatiramer acetate), with a gradual switch to group 3 (natalizumab/fingolimod). The proportion of patients using group 1 drugs alone is small and remains stable. (Groups 2 and 3 may include patients on combination therapy with group 1, while combination of groups 2 and 3 is very rare.)